Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

DSAM Partners Likes These 5 Stocks, Should You?

Page 1 of 3

DSAM Partners, a London based fund founded by Guy Shahar with an equity portfolio of $218 million, has recently filed its 13F filing for the third quarter. Given that elite funds typically perform in depth research and have the best and brightest working for them, let’s take a look at DSAM’s top stock picks: Fiat Chrysler Automobiles NV (NYSE:FCAU), Amazon.com, Inc. (NASDAQ:AMZN), Kite Pharma Inc (NASDAQ:KITE), Walgreens Boots Alliance Inc (NASDAQ:WBA), and Activision Blizzard, Inc. (NASDAQ:ATVI).

But why do we track hedge fund activity? From one point of view we can argue that hedge funds are consistently underperforming when it comes to net returns over the last three years, when compared to the S&P 500. But that doesn’t mean that we should completely neglect their activity. There are various reasons behind the low hedge fund returns. Our research indicated that hedge funds’ long positions actually beat the market. In our back-tests covering the 1999-2012 period hedge funds’ top small-cap stocks edged the S&P 500 index by double digits annually. The 15 most popular small-cap stock picks among hedge funds also bested passive index funds by around 53 percentage points over the 36 month period beginning from September 2012 (see the details here).

#5 Kite Pharma Inc (NASDAQ:KITE)

Shares held (as of September 30): 265,640
Total Value (as of September 30): $14.79 million
Percent of Portfolio (as of September 30): 4.38%

Nine analysts have a ‘Buy’ rating, and two have a ‘Hold’ rating with a consensus price target of $87.89 per share on novel cancer immunotherapy company Kite Pharma Inc (NASDAQ:KITE). Not to be left out, the elite buy-side funds are optimistic too. Of the around 730 elite funds we track, 22 funds owned $384.4 million of Kite Pharma’s shares at the end of September, versus 22 funds and $276.86 million respectively on June 30. Shares are up over 22% year-to-date so far.

 

Follow Kite Pharma Inc. (NASDAQ:KITE)
Trade (NASDAQ:KITE) Now!

#4 Amazon.com, Inc. (NASDAQ:AMZN)

Shares held (as of September 30): 37,744
Total Value (as of September 30): $19.32 million
Percent of Portfolio (as of September 30): 5.73%

Amazon.com, Inc. (NASDAQ:AMZN) shares continue to amaze, as shares have more than doubled this year on the back of the company’s fast growing Amazon Web Services division and Amazon’s sticky Prime membership. Given the division’s fast growth, healthy margins, and dominance over the infrastructure as a service market, experts estimate Amazon Web Services could be worth in excess of a hundred billion dollars in a few years (if it isn’t already). Meanwhile, Amazon Prime makes Amazon the starting point in many e-commerce related searches, providing Amazon with an opportunity to sell more of its millions of products every day.

Follow Amazon Com Inc (NASDAQ:AMZN)
Trade (NASDAQ:AMZN) Now!

Page 1 of 3
Loading Comments...